Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets open firm
Tue, 27 Jan 09:30 am

The major Asian stock markets have opened the day on a firm note with the stock markets in Japan (up 1.3%) and Singapore (up 0.6%) leading the gains. However, the stock markets in China (down 1.9%) and Hong Kong (down 0.8%) were facing selling pressure. The Indian stock markets have also opened on a positive note. Among the sectoral indices, stocks from capital goods and auto are witnessing maximum buying interest whiles software and metal stocks are leading losses.

The BSE-Sensex currently trading higher by about 121 points (up 0.43%), while the NSE-Nifty is higher by about 20 points (up 0.22%). The Midcaps and small caps have too opened the day in green, with BSE Mid Cap and BSE Small Cap indices up by 0.35 % and 0.40% respectively. The rupee was trading at Rs 61.49 to the dollar.

Energy stocks have opened the day on a firm note with Essar oil and Mangalore refinery Petrochemicals Ltd (MRPL) being the leading gainers in the pack. As per a leading financial daily, state-owned Oil and Natural Gas Corporation Ltd (ONGC) has agreed with its partner Cairn India Ltd for extending the prolific Rajasthan oil block license beyond the contractual deadline of 2020. The ONGC board has approved this extension without any conditions. Reportedly, ONGC as a licensee of the block, produces around 181,000 barrels per day of oil, pays royalty to the government on not just its 30% stake but also on Cairn's 70% interest. While the royalty is later cost recovered, the company faces cash flow issues because of having to pay in advance.

Pharma stocks have opened the day on a firm note led by Cipla Ltd and Wockhardt Ltd. As per a leading financial daily, India's biggest pharmaceutical company Sun Pharmaceuticals Ltd, which has recently acquired Ranbaxy is still open for another acquisition but will consider the business which do not require much integration effort. As per the Managing Director Dilip Sanghvi ,the company, however, would be confined to such opportunities that do not put too much pressure on the management. The Ranbaxy acquisition is under way and is expected to get concluded soon.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.